(12) Patent Application Publication (10) Pub. No.: US 2016/0361298 A1 Novick Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US 20160361298A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0361298 A1 Novick et al. (43) Pub. Date: Dec. 15, 2016 (54) METHODS AND COMPOSITIONS FOR A63/496 (2006.01) TREATING CANCER A 6LX 39/395 (2006.01) (71) Applicant: Globavir BioSciences, Inc., Los Altos, A63/496 (2006.01) CA (US) A63L/452 (2006.01) A6II 45/06 (2006.01) (72) Inventors: Paul Novick, San Francisco, CA (US); C07K 6/28 (2006.01) Jonathan Choy, Lafayette, CA (US); A6II 3/478 (2006.01) Sumit Mahajan, Foster City, CA (US); Ritika Prasad, Mountain View, CA A6II 3/167 (2006.01) (US); Shalabh Gupta, Mountain View, (52) U.S. Cl. CA (US) CPC ....... A61K 31/4174 (2013.01); A61K 31/41 78 (2013.01); A61K 31/4184 (2013.01); A61 K (21) Appl. No.: 15/179,764 3 1/496 (2013.01); A61K 31/167 (2013.01); (22) Filed: Jun. 10, 2016 A61K 31/4196 (2013.01); A61K 31/4152 (2013.01); A61K 45/06 (2013.01); C07K Related U.S. Application Data 16/2818 (2013.01); A61K 39/3955 (2013.01); (60) Provisional application No. 62/174,430, filed on Jun. A6 IK 2039/505 (2013.01) 11, 2015, provisional application No. 62/174,424, filed on Jun. 11, 2015, provisional application No. (57) ABSTRACT 62/188.413, filed on Jul. 2, 2015, provisional appli cation No. 62/195,750, filed on Jul. 22, 2015. Described are compositions and methods for treating cancer. Some methods comprise the administration of an effective Publication Classification amount of at least one inhibitor of tryptophan 2,3-dioxy (51) Int. Cl. genase (TDO) and/or indoleamine 2,3-dioxygenase (IDO), A6 IK 3/474 (2006.01) optionally combined with one or more additional anti-cancer A6 IK3I/484 (2006.01) agents. Patent Application Publication Dec. 15, 2016 Sheet 1 of 7 US 2016/0361298 A1 FIG. -- on M w * ioconazole X :1 * Deferasiox - or Nicosanide ^x to 8x Etrorro ag orcentration. -1 * Suicorazoie - Cocorazoie * - * vicaras2& 20 Coacetratio: vi Patent Application Publication Dec. 15, 2016 Sheet 2 of 7 US 2016/0361298 A1 FG 2 Wiate CD4+ T Cels u-- r Eltrombopag at 1M * Nicosamide Deferasirox * Tioconazole Concentiation at e : () on M s * Suiconazole S3 * Coconazole * Miconazole Concentratifs ... if Patent Application Publication Dec. 15, 2016 Sheet 3 of 7 US 2016/0361298 A1 FIG. 3 C88CO4- Ces -1 Eitrombopag / * Tioconazole 5 1 * Deferasirax . - Nicosamide - - - 1MT 2 Concentration - if t x -" * Miconazole - * Sulconazole 11 Cioconazole s 3. s Concertrait a Patent Application Publication Dec. 15, 2016 Sheet 4 of 7 US 2016/0361298 A1 FG, 4. C7-CD4+ T Ces r Eltrombopag /* Tioconazole 5 - * Deferasirox - * Nicosamide - or M 2} 40 Concentration -- ty as x - * Nicoagie r a (e Sulconazole s 50 Š r - Coconazole st n 9. 4- the Mi 20 40 6 Concentration -- Patent Application Publication Dec. 15, 2016 Sheet 5 of 7 US 2016/0361298 A1 F.G. 5 Wiate C3 Ces A at Mr * Nicosamide * Deferasirox ?2 ioconazole - Etrombopag 2. forcentratief -- tal s É e - she s S. 1 + Cocorazos XX - * Suiconazole 8 -- * Miconazole . Concentration w ti Patent Application Publication Dec. 15, 2016 Sheet 6 of 7 US 2016/0361298 A1 E.G. 6 CS-58 is & - Fioconazole k1 - * Deferasirox " + Nicosamide -- Eitrombopagy 2 Concertation a 1- * iconazole - Suiconazole - Cioconazole 43 (Concentration or us Patent Application Publication Dec. 15, 2016 Sheet 7 of 7 US 2016/0361298 A1 FG. 7 CB7-08 Ces - -* Tioconazole - * Deferasiox - * Nicosamide s r Eltrombopag 28 43 Concentratic t s *-* iconazole " * Suiconazole 3. 4- Coconazole e s 5 Š ae wet n 3. Concentratio -- i. US 2016/0361298 A1 Dec. 15, 2016 METHODS AND COMPOSITIONS FOR tered to the individual. In some embodiments, miconazole or TREATING CANCER a pharmaceutically acceptable salt or Solvate of miconazole is administered to the individual. In some embodiments, CROSS-REFERENCE TO RELATED Sertaconazole or a pharmaceutically acceptable salt or Sol APPLICATIONS vate of sertaconazole is administered to the individual. In 0001. This application claims the benefit of U.S. Provi Some embodiments, tioconazole or a pharmaceutically sional Application No. 62/174,430 filed Jun. 11, 2015; U.S. acceptable salt or Solvate oftioconazole is administered to Provisional Application No. 62/174,424 filed Jun. 11, 2015: the individual. In some embodiments, fenticonazole or a U.S. Provisional Application No. 62/188,413 filed Jul. 2, pharmaceutically acceptable salt or Solvate offenticonazole is administered to the individual. In some embodiments, 2015; and U.S. Provisional Application No. 62/195,750 filed liaroZole or a pharmaceutically acceptable salt or Solvate of Jul. 22, 2015; the entirety of which are incorporated by liarozole is administered to the individual. In some embodi reference herein. ments, cloconazole or a pharmaceutically acceptable salt or BACKGROUND solvate of cloconazole is administered to the individual. In Some embodiments, itraconazole or a pharmaceutically 0002 Immuno-oncology focuses on the development and acceptable salt or Solvate of itraconazole is administered to delivery of therapies that improve a body's intrinsic poten the individual. In some embodiments, niclosamide or a tial for generating an effective immune response against pharmaceutically acceptable salt or Solvate of niclosamide is cancer. Immuno-oncology therapies often target the immune administered to the individual. In some embodiments, system and not the cancer, providing the potential to treat deferasiroX or a pharmaceutically acceptable salt or Solvate cancer across a variety of tumor types. Manipulation of of deferasirox is administered to the individual. In some T-cell modulation is one method of augmenting the immune embodiments, eltrombopag or a pharmaceutically accept system to treat cancer. able salt or solvate of eltrombopag is administered to the individual. In some embodiments, the cancer comprises SUMMARY OF THE INVENTION colon cancer, pancreatic cancer, cutaneous T-cell lymphoma, 0003. The immune system has an intrinsic potential for glioma, head and neck cancer, hepatocarcinoma, leukemia, recognizing and eliminating tumor cells. However, tumors glioblastoma, colorectal cancer, gallbladder, mastocytoma, can adapt and circumvent the immune system by disrupting acute myeloid leukemia, adrenocortical cancer, bladder T-cell checkpoint pathways. An approach to disrupt tumor urothelial cancer, brain tumor, brain lower grade glioma, inhibition of the immune system involves the targeted block breast cancer, breast invasive cancer, cervical cancer, cho of checkpoint pathways Immune checkpoint pathway targets langiocarcinoma, cutaneous melanoma, diffuse large B-cell for activating therapeutic antitumor immunity include pro lymphoma, endometrial cancer, glioblastoma multiform, grammed cell death protein (PD-1) and its ligand PD-L1, H&N squamous cell carcinoma, hepatocellular carcinoma, indoleamine 2,3-dioxygenase (IDO), and cytotoxic T-lym kidney chromophobe carcinoma, lung cancer, lung adeno phocyte antigen 4 (CTLA-4). IDO is a heme-containing carcinoma, lung Squamous cell carcinoma, mesothelioma, enzyme that catalyzes the oxidation of L-tryptophan to ovarian serous cystadenocarcinoma, pancreatic adenocarci N-formyl-L-kynurenine. Another heme-containing enzyme noma, pheochromocytoma and paraganglioma, prostate that also catalyzes tryptophan degradation is tryptophan adenocarcinoma, prostate cancer, rectum adenocarcinoma, 2,3-dioxygenase (TDO). TDO has been found to be rectum cancer, renal cell cancer, renal papillary cell cancer, expressed in many tumors and this expression prevents sarcoma, testicular germ cell tumors, thymoma, thyroid tumor rejection by locally depleting tryptophan. Develop cancer, uterine carcinosarcoma, melanoma, uveal mela ment of TDO inhibitors for the treatment of tumors is an noma, or a combination thereof. In some embodiments, the active area of drug development. As the active sites of both effective amount is from about 5 mg to about 5,000 mg. In IDO and TDO enzymes are structurally similar, various Some embodiments, the individual is administered an addi inhibitors of TDO and IDO have activity against one tional active agent comprising a PD-1/PD-L pathway inhibi another. Provided in this disclosure are compounds and tor, IDO inhibitor, TDO inhibitor, CTLA-4 inhibitor, or a compositions comprising TDO inhibitors, IDO inhibitors, combination thereof. In some embodiments, the individual is and inhibitors of both TDO and IDO for active stimulation administered an additional active agent comprising BMS of the immune system. In various aspects, provided are TDO 936559, MEDI4736, MPDL3280A, MSB0010718C, AMP inhibitors, IDO inhibitors, and inhibitors of both TDO and 224, nivolumab, pembrolizumab, pidilizumab, BMS IDO that are useful for the treatment of cancer. 98.6016, MDX1105-01, avelumab, indoximod, F001287, 0004. In one aspect, provided herein is a method of NLG919, INCB024360, ipilimumab, tremelimumab, anti treating cancer comprising administering to an individual in body clone 9H10, antibody clone BNI3, Del 60, M9-14 del need thereof an effective amount of econazole, Sulconazole, 55, or a salt, solvate or combination thereof. In some isoconazole, miconazole, Sertaconazole, tioconazole, fenti embodiments, the method further comprises treating the conazole, liarozole, cloconazole, itraconazole, niclosamide, individual with an immunotherapy. In some embodiments, deferasiroX, eltrombopag, or a pharmaceutically acceptable the method further comprises treating the individual with a salt, Solvate, or combination thereof. In some embodiments, chimeric antigen receptor (CAR) T-cell therapy. In some econazole or